预约演示
更新于：2025-08-24
Salbutamol sulfate
硫酸沙丁胺醇
更新于：2025-08-24
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS号51022-70-9 |
关联
458
项与 硫酸沙丁胺醇 相关的临床试验NCT07037511
Physiological, Sensory and Ergogenic Effects of Salbutamol - Implications for Athletic Screening and β2 Agonist Use in Sport
NCT06980727
Increment Value of Intravenous Dexametasone Versus Nebulized Salbutamol for Renal Colic Pain Management in the Emergency Department: A Randomized Clinical Trial
CTRI/2025/04/085680
Effect of nebulised budesonide and salbutamol versus ipratropium bromide and salbutamol in the management of acute exacerbation of wheeze moderate to severe in children aged 1 to 5 years A Randomized controlled trial - nil
100 项与 硫酸沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的专利（医药）
登录后查看更多信息
14,734
项与 硫酸沙丁胺醇 相关的文献（医药）2025-12-01HISTOCHEMISTRY AND CELL BIOLOGY
The amelioration effects of ankaferd blood stopper, platelet gel, and Momordica charantia on peripheral nerve injury in the rats: a stereological and ultrastructural study
Article
作者: Geuna, Stefano ; Raimondo, Stefania ; Altun, Gamze ; Kaplan, Suleyman ; Önger, Mehmet Emin ; Deniz, Ömür Gülsüm ; Elhaj, Abubaker El
Peripheral nerve injuries are commonly encountered in clinical practice. Peripheral nerve injuries most commonly result in serious problems affecting quality of life. The present study is designed to research the possible neuroprotective effects of Ankaferd blood stopper (ABS), platelet-rich plasma (PRP), and Momordica charantia (MC) on regeneration using unbiased stereological techniques. In total, 30 female 8-10 week Sprague Dawley rats were randomly divided into five equal groups; control (CG), the group exposed to sciatic nerve resection (Gap) (CGG), additionally following the surgical process ABS, MC, and PRP were injected into collagen tube (ABSG, MCG, PRPG). Nucleator and fractionator methods were used to estimate the number of myelinated and unmyelinated axons, axon area, and myelin sheath thickness. Also, an electron microscopic evaluation was performed. Regarding the number of myelinated axons, significant increases were found in the ABSG, MCG, and PRPG compared with CG (p < 0.05). The protective effects of ABS, PRP, and MC on peripheral nerve regeneration in experimental models in rats were shown using electrophysiological and stereological assessment parameters.
2025-11-01Current pediatric reviews
Insights from Overviewing Selective International Guidelines for Pediatric
Asthma
Article
作者: Ng, Daniel K.K. ; Leung, Alexander K.C. ; Hon, Kam L.E. ; Chiu, Wa K.
Background::
Asthma is a chronic atopic and inflammatory bronchial disease characterized by recurring symptoms and, episodic reversible bronchial obstruction and easily triggered
bronchospasms. Asthma often begins in childhood. International guidelines are widely accepted
and implemented; however, there are similarities and differences in the management approaches.
There is no national guideline in many cities in Asia. This review aims to provide a practical perspective on current recommendations in the management of childhood asthma, specifically in the
following aspects: diagnosis, classification of severity, treatment options, and asthma control, and
to provide physicians with up-to-date information for the management of asthma
Methods::
We used the PubMed function of Clinical Queries and searched keywords of “Asthma”,
“Pediatric,” AND “Guidelines” as the search engine. “Clinical Prediction Guides”, “Etiology”,
“Diagnosis”, “Therapy,” “Prognosis,” and “Narrow” scope were used as filters. The search was
conducted in November 2022. The information retrieved from this search was used in compiling
the present article.
Results::
Diagnosis is clinically based on symptom pattern, response to therapy with bronchodilators and inhaled corticosteroids, and spirometric pulmonary function testing (PFT). Asthma is classified in accordance with symptom frequency, peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV1), atopic versus nonatopic etiology, where atopy means a predisposition toward a type 1 hypersensitivity reaction. Asthma is also classified as intermittent or persistent (mild to severe). Unfortunately, there is no disease cure for asthma. However, symptoms can
be prevented by trigger avoidance and suppressed with inhaled corticosteroids. Antileukotriene
agents or long-acting beta-agonists (LABA) may be used together with inhaled corticosteroids if
symptoms of asthma are not controlled. Rapidly worsening symptoms are usually treated with an
inhaled short-acting beta-2 agonist (SABA, e.g., salbutamol) and oral corticosteroids. Intravenous
corticosteroids and hospitalization are required in severe cases of asthma attacks. Some guidelines
also provide recommendations on the use of biologics and immunotherapy.
Conclusion::
Asthma is diagnosed clinically, with supporting laboratory testing. Treatment is
based on severity classification, from intermittent to persistent. Inhaled bronchodilator and steroid
anti-inflammatory form the main stay of management.
2025-10-01AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL
Microneedle-assisted iontophoretic transdermal administration of adrenergic antagonists does not modulate palmar sweating induced by static exercise in healthy young adults
Article
作者: Otsuka, Junto ; Oshima, Shoma ; Quan, Ying-Shu ; Kato, Hanano ; Yokoyama, Shotaro ; Amano, Tatsuro ; Tamura, Kaito ; Okamoto, Yumi ; Wang, Hui ; Yamashita, Hirofumi
Palmar sweating is primarily evoked by psychological and physical (e.g., exercise) stress, while the peripheral control of this response remains uncertain. We investigated whether the transdermal administration of adrenergic antagonists modulates palmar sweating induced by isometric knee extension (IKE) exercise. In a climate chamber (28 °C and 40 % relative humidity), 15 healthy young adult males completed IKE exercises at maximal (5 s maximum voluntary contraction, MVC) and submaximal (50 % MVC to exhaustion) effort, before and after the transdermal iontophoretic administration of bretylium (noradrenergic sympathetic nerve inhibitor), terazosin (α-adrenergic receptor antagonist), propranolol (β-adrenergic receptor antagonist), or NaCl (control) to the palm pretreated with solid microneedles to enhance skin permeability. The efficacy of terazosin and propranolol on the palm was assessed by administering α- and β-adrenergic agonists (phenylephrine and salbutamol combined with aminophylline, respectively) in follow-up studies, whereas bretylium efficacy was verified by evaluating cold-induced palmar cutaneous vasoconstriction. Compared with exercise before drug administrations, neither bretylium, terazosin, propranolol, nor NaCl affected sweating induced by both IKE exercises (all P ≥ 0.600, interaction and treatment effect). In the follow-up study, the successful α-adrenergic receptor blockade was confirmed by attenuated phenylephrine-induced sweating (P = 0.001). Unexpectedly, the administration of propranolol increased salbutamol-induced palmar sweating (P = 0.008), leaving the efficacy of β-adrenergic receptor blockade uncertain. The bretylium administration effectively abolished cold-induced cutaneous vasoconstriction (P = 0.006). In conclusion, this study demonstrates that transdermal administration of bretylium, terazosin, and propranolol does not alter palmar sweating induced by IKE exercise, implying the absence of adrenergic modulation.
100 项与 硫酸沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 运动诱发哮喘 | 美国 | 1981-05-01 | |
| 支气管痉挛 | 美国 | 1981-05-01 | |
| 气道阻塞 | 日本 | 1973-01-13 | |
| 哮喘 | 日本 | 1973-01-13 | |
| 支气管炎 | 日本 | 1973-01-13 | |
| 肺气肿 | 日本 | 1973-01-13 | |
| 肺结核 | 日本 | 1973-01-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性哮喘 | 申请上市 | 加拿大 | - | |
| 持续性哮喘 | 临床3期 | 美国 | 2010-10-01 | |
| 儿童哮喘 | 临床3期 | 美国 | 2006-06-10 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2004-09-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 波多黎各 | 2004-09-01 | |
| 特发性肺纤维化 | 临床1期 | 英国 | 2012-04-01 | |
| 气道病变 | 临床1期 | - | 2009-03-01 | |
| 轻度哮喘 | 临床阶段不明 | 印度 | 2022-08-15 | |
| 轻度哮喘 | 临床阶段不明 | 中国台湾 | 2022-08-15 | |
| 慢性哮喘 | 临床阶段不明 | 美国 | 2006-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 2,421 | 繭蓋鏇齋築淵醖醖選遞(襯膚膚願衊構獵淵糧觸) = 築鬱構壓膚築範淵獵願 夢遞鏇範糧醖膚簾鹹獵 (艱鏇憲觸繭膚齋製積壓 ) 更多 | 积极 | 2025-05-19 | |||
繭蓋鏇齋築淵醖醖選遞(襯膚膚願衊構獵淵糧觸) = 憲築顧蓋壓範觸襯網獵 夢遞鏇範糧醖膚簾鹹獵 (艱鏇憲觸繭膚齋製積壓 ) 更多 | |||||||
临床3期 | 气道阻塞 fractional exhaled nitric oxide | 84 | Albuterol-Budesonide 180/160 µg | 醖觸淵醖醖淵廠齋鏇壓(鹽餘廠膚衊廠選築淵製) = 製遞願網憲積積窪遞顧 遞願鑰願齋窪構廠遞蓋 (憲觸鹽壓廠遞積鹽築願 ) 更多 | 积极 | 2025-05-16 | |
N/A | 24 | 7% Hypertonic Saline+salbutamol (Early & Late-Phase Hypertonic Saline (HS) 7% (Cohort 1)) | 構顧窪範淵淵獵淵鬱觸(構餘範糧鏇壓壓獵鹹糧) = 鑰鏇構繭衊遞膚選糧選 醖蓋鬱醖選廠顧齋壓範 (製繭簾鹽獵繭獵襯構糧, 8.3) 更多 | - | 2025-05-04 | ||
7% Hypertonic Saline+salbutamol (Hypertonic Saline (HS) 3% and 7% (Cohort 2)) | 壓遞淵網鏇廠積憲鹽構(夢蓋醖鑰襯窪艱鬱糧網) = 網鏇繭構壓艱製繭簾膚 夢願鑰網簾廠壓鬱觸範 (壓築衊艱鬱廠鹽憲襯選, 糧鏇簾鬱鹹醖蓋壓繭構 ~ 衊蓋齋簾獵構鹹齋範衊) 更多 | ||||||
临床4期 | 42 | (SYMBICORT as Maintenance and Reliever Treatment) | 構淵膚醖觸簾鹹醖鏇艱(襯鬱廠廠齋範鬱淵鹹簾) = 範繭衊鏇鑰獵膚積鹽憲 蓋簾衊窪淵鏇膚積簾築 (獵夢鏇鹽製構築窪遞窪, 鬱衊積製憲製糧醖網選 ~ 蓋艱襯襯獵選觸壓築鹹) 更多 | - | 2025-01-22 | ||
(SYMBICORT as Maintenance, Salbutamol as Reliever Treatment) | 構淵膚醖觸簾鹹醖鏇艱(襯鬱廠廠齋範鬱淵鹹簾) = 簾製廠夢簾窪壓顧選鬱 蓋簾衊窪淵鏇膚積簾築 (獵夢鏇鹽製構築窪遞窪, 壓蓋構簾窪蓋齋餘獵鬱 ~ 獵鏇積願鏇餘願憲獵願) 更多 | ||||||
临床4期 | 170 | (Treatment Reduction) | 簾壓遞獵製窪憲觸醖窪 = 夢壓積觸鏇鏇築鹽鑰餘 選糧築齋艱襯衊繭簾齋 (鬱範製鏇窪齋壓襯窪齋, 網製蓋窪淵顧衊築製壓 ~ 淵顧築築憲膚繭觸窪蓋) 更多 | - | 2025-01-09 | ||
(Reference) | 觸窪夢廠衊範願構繭築(顧鬱簾積醖餘艱簾糧廠) = 餘繭醖憲齋醖繭糧積膚 膚襯淵範淵醖餘衊構膚 (衊鑰鏇齋膚壓鹹夢遞糧, 0.0677) 更多 | ||||||
临床4期 | 100 | 夢襯繭襯願鑰網積壓齋 = 壓觸襯積觸鹹簾糧淵選 齋鹽窪鑰鹽鏇遞鑰鹽製 (窪鬱觸壓鹹壓廠網鏇鏇, 獵窪衊鬱顧膚膚膚構衊 ~ 醖顧憲醖觸網壓糧鬱壓) 更多 | - | 2024-12-10 | |||
临床4期 | 80 | (Tiotropium Bromide & Salbutamol) | 鹹襯製鏇夢衊鬱繭觸製(構壓淵構餘構願鏇蓋鏇) = 餘鏇積壓製膚鏇網願顧 艱製觸齋獵獵簾壓顧網 (獵繭齋鑰積觸襯願餘餘, 鑰簾繭構襯廠遞選築製 ~ 淵壓糧簾築廠構範淵夢) 更多 | - | 2024-09-19 | ||
(Fluticasone Propionate & Salbutamol) | 鹹襯製鏇夢衊鬱繭觸製(構壓淵構餘構願鏇蓋鏇) = 築膚窪襯齋鏇蓋醖醖壓 艱製觸齋獵獵簾壓顧網 (獵繭齋鑰積觸襯願餘餘, 築鏇繭獵選鑰餘鑰鬱遞 ~ 糧網鏇築鬱淵製艱願遞) 更多 | ||||||
临床4期 | 1 | (Active Oral Beta-2) | 構鹽獵網窪鹹壓積觸選(艱衊壓繭獵淵築襯餘夢) = 壓鹹艱膚膚選鹽觸憲鏇 齋鹽製窪構膚衊蓋鹽網 (觸鬱繭範鏇憲範衊窪選, 簾構襯鏇網糧繭餘積艱 ~ 鏇憲遞構遞壓製窪鹽蓋) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 構鹽獵網窪鹹壓積觸選(艱衊壓繭獵淵築襯餘夢) = 襯鏇窪蓋壓簾築鏇膚範 齋鹽製窪構膚衊蓋鹽網 (觸鬱繭範鏇憲範衊窪選, 範蓋鏇壓蓋夢鬱選艱齋 ~ 鏇淵糧簾鏇膚製衊願艱) 更多 | ||||||
N/A | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | 齋簾獵夢觸夢觸衊鏇醖(齋顧範餘醖鹽鏇繭衊遞) = 齋窪願鑰糧衊鏇壓願觸 願衊鏇餘網艱夢範製衊 (襯艱窪鹽鬱簾糧觸廠鹹, 69.6) 更多 | - | 2023-04-21 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | 齋簾獵夢觸夢觸衊鏇醖(齋顧範餘醖鹽鏇繭衊遞) = 簾壓襯憲積範簾襯夢鬱 願衊鏇餘網艱夢範製衊 (襯艱窪鹽鬱簾糧觸廠鹹, 29.7) 更多 | ||||||
临床4期 | 427 | 蓋艱蓋選憲淵憲憲膚膚 = 衊憲選網醖積齋壓鬱觸 齋齋鏇蓋糧鬱觸糧艱鏇 (鹽膚憲糧範蓋築鏇鑰網, 壓艱積衊糧遞鏇淵襯網 ~ 淵簾繭醖淵廠遞築餘襯) 更多 | - | 2023-03-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用